CanSino Biologics Inc
SSE:688185

Watchlist Manager
CanSino Biologics Inc Logo
CanSino Biologics Inc
SSE:688185
Watchlist
Price: 62.11 CNY -8.12% Market Closed
Market Cap: 7.1B CNY
Have any thoughts about
CanSino Biologics Inc?
Write Note

CanSino Biologics Inc
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

CanSino Biologics Inc
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
CanSino Biologics Inc
SSE:688185
Research & Development
-ÂĄ568.4m
CAGR 3-Years
-12%
CAGR 5-Years
-41%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Research & Development
-ÂĄ2.1B
CAGR 3-Years
-19%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Research & Development
-ÂĄ232.3m
CAGR 3-Years
-31%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Research & Development
-ÂĄ5.8B
CAGR 3-Years
0%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
Research & Development
-ÂĄ339.2m
CAGR 3-Years
-19%
CAGR 5-Years
-22%
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Research & Development
-ÂĄ712.5m
CAGR 3-Years
-61%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

CanSino Biologics Inc
Glance View

Market Cap
7.1B CNY
Industry
Pharmaceuticals

CanSino Biologics Inc is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Tianjin, Tianjin and currently employs 1,946 full-time employees. The company went IPO on 2019-03-28. CanSino Biologics Inc is a clinical-stage vaccine company in China. The firm's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia.

Intrinsic Value
67.83 CNY
Undervaluation 8%
Intrinsic Value
Price

See Also

What is CanSino Biologics Inc's Research & Development?
Research & Development
-568.4m CNY

Based on the financial report for Dec 31, 2023, CanSino Biologics Inc's Research & Development amounts to -568.4m CNY.

What is CanSino Biologics Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-41%

Over the last year, the Research & Development growth was 22%. The average annual Research & Development growth rates for CanSino Biologics Inc have been -12% over the past three years , -41% over the past five years .

Back to Top